Associated Papers
A uniquely efficacious type of CFTR corrector with complementary mode of action.
Marchesin V et al.
Science Advances, 2024
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
Laselva O et al.
Molecular Pharmacology, 2018
Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue.
Molinski SV et al.
Embo Molecular Medicine, 2017
The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
Laselva O et al.
Biochemical Pharmacology, 2016
Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.
Molinski SV et al.
Journal of Biomolecular Screening, 2015
Select a paper to view details